Press Releases

2018.08.07 Corporate PDF (87KB)
Daiichi Sankyo Announces Change in Principal Shareholders
2018.08.01 R&D PDF (49KB)
FDA Grants Breakthrough Therapy Designation to Daiichi Sankyo’s FLT3 Inhibitor Quizartinib for Relapsed/Refractory FLT3-ITD AML
2018.07.31 Corporate PDF (205KB)
Daiichi Sankyo Announces Split off (Simple Absorption-type Split) and Transfer of 41 Long-listed Products in Japan
2018.07.31 Corporate PDF (104KB)
Daiichi Sankyo Announces Reversal of Tax-related Expenses in its Non-consolidated Financial Results (Japanese GAAP)
2018.07.30 Corporate PDF (242KB)
Daiichi Sankyo Enters Worldwide Licensing Agreement with Glycotope for Gatipotuzumab Antibody Drug Conjugate
2018.07.17 Corporate PDF (85KB)
Daiichi Sankyo Announces Completion of Payment Concerning Disposal of Treasury Shares as Restricted Share-Based Remuneration
2018.07.02 Products PDF (98KB)
Daiichi Sankyo Obtains Approval for Additional Indication and Dosage for DiagnogreenⓇ for Injection 25 mg in Japan
2018.06.18 Corporate PDF (121KB)
Daiichi Sankyo Announces Disposal of Treasury Shares as Restricted Share-Based Remuneration
2018.06.18 R&D PDF (249KB)
Phase 3 QuANTUM-R Study Demonstrates Daiichi Sankyo’s Quizartinib Significantly Prolongs Overall Survival as Single Agent Compared to Chemotherapy in Patients with Relapsed/Refractory AML with FLT3-ITD Mutations
2018.06.15 Products PDF (89KB)
Daiichi Sankyo Launches FENTANYL CITRATE TAPE for 1day “DAIICHI SANKYO” in Japan for Long-Acting Cancer Pain Relief
2018.06.06 Corporate PDF (97KB)
Daiichi Sankyo’s U.S. Products Liability Litigation Settlement Program Moves Forward; More than 97 Percent of Eligible Litigants and Claimants Opt In (Update on previously disclosed item)
2018.06.05 R&D PDF (76KB)
Daiichi Sankyo Presents Phase 3 ENLIVEN Study of Pexidartinib, Demonstrating Statistically Significant Clinical Improvement Across Multiple Endpoints in Patients with Tenosynovial Giant Cell Tumor at 2018 American Society of Clinical Oncology (ASCO) Annual Meeting
2018.06.01 R&D PDF (86KB)
Daiichi Sankyo Presents Long-Term Phase 1 Results of Antibody Drug Conjugate DS-8201 in Patients with HER2-Expressing Breast, Gastric and Other Solid Cancers at 2018 American Society of Clinical Oncology (ASCO) Annual Meeting
2018.06.01 R&D PDF (271KB)
Daiichi Sankyo Presents Preliminary Phase 1 Data for Antibody Drug Conjugate U3-1402 in Patients with HER3-Expressing Breast Cancer at 2018 American Society of Clinical Oncology (ASCO) Annual Meeting
2018.05.31 R&D PDF (189KB)
Daiichi Sankyo Initiates Phase 2 Study of DS-8201 in Patients with Advanced HER2-Overexpressing or HER2-Mutated Non-Squamous Non-Small Cell Lung Cancer
2018.05.30 Corporate PDF (98KB)
Daiichi Sankyo U.S. subsidiary, Luitpold Pharmaceuticals, Inc., to Be Merged with Its Own Subsidiaries and Renamed
2018.05.30 Corporate PDF (239KB)
Daiichi Sankyo Announces Launch of Immune-mediated Inflammatory Diseases Consortium for Drug Development
2018.05.16 Products PDF (115KB)
Daiichi Sankyo Launches NaruveinⓇ Injection for Cancer Pain Treatment in Japan
2018.05.15 R&D PDF (171KB)
Zymeworks and Daiichi Sankyo Expand Immuno-Oncology Collaboration Focused on Bispecific Antibodies
2018.05.11 Corporate PDF (132KB)
Daiichi Sankyo Announces Changes to Representative Directors and Members of the Audit and Supervisory Board
2018.05.11 Corporate PDF (76KB)
Daiichi Sankyo Announces Changes to Members of the Board and Members of the Audit and Supervisory Board at Subsidiaries in Japan
2018.05.08 R&D PDF (271KB)
Daiichi Sankyo Announces Single Agent Quizartinib Significantly Prolongs Overall Survival Compared with Chemotherapy in Patients with Relapsed/Refractory AML with FLT3-ITD Mutations (QuANTUM-R Study)
2018.05.08 Products PDF (92KB)
Daiichi Sankyo and Kaketsuken to end sales cooperation for Influenza HA Vaccine “Kaketsuken” and hepatitis B vaccine Bimmugen®
2018.04.27 Corporate PDF (97KB)
Daiichi Sankyo to Reorganize Kitasato Daiichi Sankyo Vaccine into Specialized Manufacturing Subsidiary
2018.04.25 R&D PDF (87KB)
Daiichi Sankyo Announces Phase 1/2 Clinical Trial Results for DS-5141 (Therapeutic Agent for Duchenne Muscular Dystrophy) in Japan
2018.04.18 Products PDF (109KB)
AstraZeneca and Daiichi Sankyo Launch Proton Pump Inhibitor Nexium® 10 mg and 20 mg Granules for Suspension, Sachet, in Japan
2018.04.05 Corporate PDF (201KB)
Daiichi Sankyo and DarwinHealth Enter Exclusive Research Collaboration for Novel Cancer Target Initiative
2018.03.30 Corporate PDF (97KB)
Daiichi Sankyo Agrees to Modify the Terms of the Settlement Program for U.S. Olmesartan Products Liability Litigation
2018.03.27 R&D PDF (51KB)
Daiichi Sankyo’s HER2-Targeting Antibody Drug Conjugate DS-8201 Receives SAKIGAKE Designation for Gastric Cancer from Japan MHLW
2018.03.27 R&D PDF (104KB)
Nagoya City University, Chubu University, Daiichi Sankyo and Mitsubishi UFJ Capital Announce Open Innovation Research on New Cancer Hyperthermia Therapy in Japan
2018.03.26 Products PDF (83KB)
Japanese Government to Stockpile Inavir® Anti-influenza Drug for Combatting Pandemic Influenza Threats in Japan
2018.03.23 Corporate PDF (92KB)
Daiichi Sankyo Announces Status Relating to Acquisition of Own Shares and Completion of Acquisition
2018.03.08 R&D PDF (216KB)
Daiichi Sankyo Initiates Phase 2 Study of DS-8201 in Patients with HER2-Expressing Advanced Colorectal Cancer
2018.03.01 Corporate PDF (29KB)
Daiichi Sankyo, Inc. Aligns U.S. Commercial Operations to Current Portfolio and Upcoming Cancer Pipeline
2018.03.01 Corporate PDF (90KB)
Daiichi Sankyo Announces Status Relating to Acquisition of Own Shares
2018.02.27 Products PDF (121KB)
Daiichi Sankyo Announces NDA submission in Japan of Esaxerenone for Treatment of Hypertension
2018.02.26 Corporate PDF (92KB)
Daiichi Sankyo Reports Rupture of Liquid Storage Tank at Kitamoto Facility of Kitasato Daiichi Sankyo Vaccine
2018.02.23 R&D PDF (181KB)
Daiichi Sankyo Initiates Phase 1 Study of DS-1062 in Patients with Advanced Non-Small Cell Lung Cancer
2018.02.23 Corporate PDF (117KB)
Daiichi Sankyo Appoints New Group Corporate Officers
2018.02.23 Corporate PDF (88KB)
Daiichi Sankyo Announces Organizational Restructuring Effective as of April 1, 2018
2018.02.22 Products PDF (111KB)
Daiichi Sankyo Submits Application for Additional Indication and Dosage for DiagnogreenⓇ for Injection 25 mg in Japan
2018.02.21 Corporate PDF (135KB)
Daiichi Sankyo Selected for 2018 Certified Health and Productivity Management Organization (White 500)
2018.02.15 R&D PDF (109KB)
Daiichi Sankyo Submits Marketing Application for Mirogabalin in Japan
2018.02.07 R&D PDF (182KB)
Daiichi Sankyo Initiates Phase 1 Study of U3-1402 in Patients with Metastatic EGFR-Mutated Non-Small Cell Lung Cancer
2018.02.02 CSR PDF (125KB)
Daiichi Sankyo Selected for Silver Class of RobecoSAM Sustainability Award 2018
2018.02.02 R&D PDF (92KB)
Daiichi Sankyo Announces Update on Amgen Inc.’s Phase 3 Clinical Trial Evaluating Denosumab as Adjuvant Breast Cancer Treatment
2018.02.01 Corporate PDF (90KB)
Daiichi Sankyo Announces Status Relating to Acquisition of Own Shares
2018.01.31 Corporate PDF (90KB)
Daiichi Sankyo to Record Loss on Valuation of Kitasato Daiichi Sankyo Vaccine Co., Ltd. Shares in Non-consolidated Accounts
2018.01.19 Products PDF (132KB)
Nexium® 10 mg and 20 mg Capsules received additional approval of paediatric dosage and administration, and marketing approval of Nexium® 10 mg and 20 mg Granules for Suspension, Sachet in Japan
2018.01.19 R&D PDF (272KB)
Daiichi Sankyo Presents Updated Data for DS-8201 in Patients with HER2-Expressing Gastric Cancer at ASCO 2018 Gastrointestinal Cancers Symposium
2018.01.05 Corporate PDF (90KB)
Daiichi Sankyo Announces Status Relating to Acquisition of Own Shares

In order to view the PDF files, you need to have the latest version of Adobe Reader installed.